NCT00660244已完成不适用
Breast Cancer Tumor Care Patient Observation Programme
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Progression of disease and tolerability in general
研究概览
简要总结
The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women
- •Already on upfront Arimidex Therapy (Start 1-4 weeks before)
排除标准
- •Premenopausal women
- •Tamoxifen switch patients
研究组 & 干预措施
1
干预措施: anastrozole (Drug)
结局指标
主要结局
Progression of disease and tolerability in general
时间窗: Baseline, every 3 month
次要结局
- Patient questionnaire to collect data on Incidence, time of onset and treatment of arthralgia(Baseline, every 3 month)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast CancerBreast CancerNCT00544986AstraZeneca
已完成
2 期
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal WomenDCISNCT00256217Rita Sanghvi, Mehta42
已完成
不适用
Abraxane in Treatment of Metastatic Breast CancerMetastatic Breast CancerNCT02555696Celgene203
已完成
不适用
An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neuBreast CancerNCT00153218Cancer Research Network94
进行中（未招募）
不适用
ATTE: Long-term Anastrozole versus Tamoxifen Treatment EffectsCancerBreast cancerISRCTN86305500Queen Mary University of London (UK)1,342